CRISPR, KSQ Therapeutics join forces to advance cell therapies in oncology

The agreement allows CRISPR, a Swiss gene editing company, to gain access to the KSQ Therapeutics’ intellectual property (IP) for editing certain gene targets in its allogeneic oncology

The post CRISPR, KSQ Therapeutics join forces to advance cell therapies in oncology appeared first on Pharmaceutical Business review.

Trialbee and TriNetX partner to accelerate patient-centric clinical trials

“This partnership will significantly widen Trialbee’s service offerings to drive patient recruitment and retention,” said Lollo Eriksson, CEO of Trialbee. “This is a great opportunity to leverage both

The post Trialbee and TriNetX partner to accelerate patient-centric clinical trials appeared first on Pharmaceutical Business review.

Sun Pharma launches Drizalma Sprinkle in US

Drizalma Sprinkle is a serotonin and norepinephrine reuptake inhibitor (SNRI) designed for the treatment of various neuro-psychiatric and pain disorders in patients who have difficulty swallowing – a

The post Sun Pharma launches Drizalma Sprinkle in US appeared first on Pharmaceutical Business review.

Acino to buy Takeda’s select OTC and prescription pharmaceutical assets for $200m

The divestment is part of Takeda’s strategy to focus on core business areas and facilitate rapid deleveraging following its acquisition of Shire. Takeda growth and emerging markets business

The post Acino to buy Takeda’s select OTC and prescription pharmaceutical assets for $200m appeared first on Pharmaceutical Business review.

Thermo Fisher launches IonicX XRF Analyzer to identity ionic salts

According to the life sciences company, the technology used by the IonicX XRF Analyzer helps save time and money that is otherwise used on conventional analysis techniques. This

The post Thermo Fisher launches IonicX XRF Analyzer to identity ionic salts appeared first on Pharmaceutical Business review.

Kyowa Kirin launches NOURIANZ in US for treatment of Parkinson’s disease “Off” episodes

Over time, patients taking levodopa may begin to experience periods when PD symptoms, including motor fluctuations, re-emerge between treatment doses. These are called “off” episodes. “We are pleased

The post Kyowa Kirin launches NOURIANZ in US for treatment of Parkinson’s disease “Off” episodes appeared first on Pharmaceutical Business review.

Forbius completes enrollment into phase 1a solid tumour trial of AVID200

Simultaneously, the company completed a Series C financing led by HBM Partners with participation from new and existing investors. AVID200 is rationally designed to selectively and potently inhibit

The post Forbius completes enrollment into phase 1a solid tumour trial of AVID200 appeared first on Pharmaceutical Business review.

Janssen, Bayer get FDA nod for Xarelto to prevent VTE in acutely ill medical patients

The approval has been granted for Xarelto to prevent venous thromboembolism (VTE) or blood clots in hospitalised acutely ill medical patients at risk for thromboembolic complications who are

The post Janssen, Bayer get FDA nod for Xarelto to prevent VTE in acutely ill medical patients appeared first on Pharmaceutical Business review.

MabThera meets primary endpoint in PEMPHIX trial in pemphigus vulgaris

The PEMPHIX trial also showed that MabThera was superior to mycophenolate mofetil (MMF) in the late-stage trial held in adult patients. PEMPHIX has been taken up by Roche

The post MabThera meets primary endpoint in PEMPHIX trial in pemphigus vulgaris appeared first on Pharmaceutical Business review.

Pfizer presents positive phase 3 data for abrocitinib in moderate to severe atopic dermatitis

Abrocitinib, an investigational oral Janus kinase 1 (JAK1) inhibitor, met all the co-primary and key secondary endpoints, which were related to skin clearance and itch relief compared to

The post Pfizer presents positive phase 3 data for abrocitinib in moderate to severe atopic dermatitis appeared first on Pharmaceutical Business review.